NCT02498613 2025-09-25
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
9 trialsNCT02016872 2025-04-30
Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT00606294 2023-06-28
Using Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission Tomography To Detect Hypoxia in Head and Neck Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT03303469 2021-02-21
Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging
University of Alabama at Birmingham
Phase 2 Terminated
NCT02471313 2019-04-23
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00902577 2019-04-08
MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT01169350 2017-11-17
18F-Fluoromisonidazole and Fludeoxyglucose F 18 PET/CT Patients With Soft Tissue Sarcoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00559377 2016-12-30
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00544674 2012-12-10
PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer
Proacta, Incorporated
Phase 2 Terminated